EGFR and non-small cell lung carcinoma: EGFR tyrosine kinase inhibitors (TKIs) can remarkably improve progression-free survival (PFS) and are recommended as the first-line treatment for EGFR-mutated metastatic NSCLC according to the NCCN guidelines [6,7].